Non‐surgical interventions for nystagmus developing in the first year of life (infantile nystagmus)
Appendices
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Nystagmus, Congenital] this term only
#2 (congenital or idiopathic or infantile) near/3 nystagm*
#3 #1 or #2
#4 MeSH descriptor: [Eyeglasses] explode all trees
#5 spectacles or glasses
#6 MeSH descriptor: [Contact Lenses] explode all trees
#7 contact lens*
#8 MeSH descriptor: [Photorefractive Keratectomy] explode all trees
#9 keratectom*
#10 PRK
#11 MeSH descriptor: [Keratomileusis, Laser In Situ] explode all trees
#12 keratomileusis
#13 LASIK
#14 laser
#15 prism
#16 MeSH descriptor: [Pattern Recognition, Visual] explode all trees
#17 MeSH descriptor: [Photic Stimulation] explode all trees
#18 rapid serial visual presentation
#19 oscilloscope*
#20 optical near/2 device*
#21 occlu*
#22 patch*
#23 shield*
#24 MeSH descriptor: [Mydriatics] explode all trees
#25 mydriat*
#26 cyclopleg*
#27 MeSH descriptor: [Atropine] explode all trees
#28 atropine*
#29 #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
#30 #3 and #29
Appendix 2. MEDLINE (OvidSP) search strategy
1. Nystagmus, Congenital/
2. ((congenital or idiopathic or infantile) adj3 nystagm$).tw.
3. or/1‐2
4. exp eyeglasses/
5. (spectacles or glasses).tw.
6. exp contact lenses/
7. contact lens$.tw.
8. exp photorefractive keratectomy/
9. keratectom$.tw.
10. PRK.tw.
11. keratomileusis, laser in situ/
12. keratomileusis.tw.
13. LASIK.tw.
14. laser.tw.
15. prism.tw.
16. Pattern Recognition, Visual/
17. Photic Stimulation/
18. rapid serial visual presentation.tw.
19. oscilloscope$.tw.
20. (optical adj2 device$).tw.
21. occlu$.tw.
22. patch$.tw.
23. shield$.tw.
24. exp mydriatics/
25. mydriat$.tw.
26. cyclopleg$.tw.
27. exp atropine/
28. atropine$.tw.
29. or/4‐28
30. 3 and 29
Appendix 3. EMBASE (OvidSP) search strategy
1. congenital nystagmus/
2. ((congenital or idiopathic or infantile) adj3 nystagm$).tw.
3. or/1‐2
4. exp spectacles/
5. (spectacles or glasses).tw.
6. exp contact lens/
7. (contact adj2 lens$).tw.
8. exp photorefractive keratectomy/
9. keratectom$.tw.
10. PRK.tw.
11. keratomileusis/
12. keratomileusis.tw.
13. LASIK.tw.
14. laser.tw.
15. prism.tw.
16. pattern recognition/
17. photostimulation/
18. rapid serial visual presentation.tw.
19. oscilloscope$.tw.
20. (optical adj2 device$).tw.
21. occlu$.tw.
22. patch$.tw.
23. shield$.tw.
24. exp mydriatic agent/
25. mydriat$.tw.
26. cyclopleg$.tw.
27. exp atropine/
28. atropine$.tw.
29. or/4‐28
30. 3 and 29
Appendix 4. metaRegister of Controlled Trials search strategy
(congenital or idiopathic or infantile) and nystagmus
Appendix 5. ClinicalTrials.gov search strategy
(Congenital OR Idiopathic OR Infantile) AND Nystagmus
Appendix 6. ICTRP search strategy
Search 1 ‐ congenital AND nystagmus
Search 2 ‐ infantile AND nystagmus
Search 3 ‐ idiopathic AND nystagmus
| Participant characteristics | Total number Gender Age Country Type of nystagmus Diagnostic criteria Comorbidities Baseline binocular visual acuity or changed in best corrected binocular visual acuity Orthoptic assessment Participant inclusion and exclusion criteria |
| Intervention | Intervention Frequency and treatment length |
| Study and methodology | Study design Trial identifiers Study size Randomisation Masking, allocation concealment Duration of each study |
| Primary outcomes | Change in best corrected binocular visual acuity (logMAR or Snellen chart) |
| Secondary outcomes | Estimated visual acuity using visual evoked potentials and/or nystagmus acuity functions such as NAFX Eye movement recordings using any available technique (e.g. video recording, infrared limbal tracker, electro‐oculography). Amplitude (mean and minimum); intensity; foveation time; position (mean, minimum mean in foveation window, standard deviation); velocity (mean, minimum mean in foveation window, standard deviation); null zone position and width. Head posture measured in degrees Visual recognition times Patient satisfaction and functional measurements (using validated questionnaires e.g. VFQ‐25) Economic data and cost analysis data |
| Adverse outcomes | Adverse effects (minor or major: reduction in visual acuity and blindness; double vision; cognitive effects; death) |
| Additional data | Treatment compliance and losses to follow‐up |
| Missing data | Intention‐to‐treat analysis if possible Trial authors contacted? |
| Data collection | Microsoft Excel® spreadsheet |
